Ben-Gurion University of the Negev (BGU) researchers reveal in a new, large-scale study that "normal" blood pressure at age 17 can still predict hypertension at early adulthood and that teenage boys are three to four times more likely to develop high blood pressure in early adulthood than girls.

Daiichi Sankyo, Inc. announced that the US Food and Drug Administration (FDA) approved Tribenzor (olmesartan medoxomil, amlodipine, hydrochlorothiazide), a new three-in-one combination product taken once-daily for the treatment of hypertension in patients who are not adequately controlled on any two of the following antihypertensive drug classes: angiotensin receptor blockers, calcium channel ...

Federal drug regulators approved Daiichi Sankyos Tribenzor, a prescription drug that combines three medicines to provide a simpler treatment regimen for patients with high blood pressure. The once-daily treatment is intended for patients whose blood pressure is not adequately controlled...

MONDAY, July 26 (HealthDay News) -- Tribenzor, a three-in-one drug to treat high blood pressure, has been approved by the U.S. Food and Drug Administration.

Daiichi Sankyo, Inc. announced today that the U.S. Food and Drug Administration approved TRIBENZOR�� , a new three-in-one combination product taken once-daily for the treatment of hypertension in patients who are not adequately controlled on any two of the following antihypertensive drug classes: angiotensin receptor blockers, calcium channel blockers and diuretics.